Tris Pharma is a pharmaceutical company that provides treatment options for Attention Deficit Hyperactivity Disorder (ADHD). It offers products designed for patients six years and older and utilizes advanced Liqui XR technology. This technology enables products to deliver Immediate Release (IR) and Extended Release (ER) effects from morning through evening, providing all-day consistency without drop-offs in medication release.
The Tris Pharma product lineup includes the DYANAVEL XR tablet, DYANAVEL XR oral suspension, Quillivant XR, and QuilliChew ER. DYANAVEL XR is available in both tablet and oral suspension form, designed to offer efficacy, safety, and easy dosing for the patients. Furthermore, Tris Pharma provides extensive information about each product, including patient profiles, PK data, safety data, and dosing instructions.
The company's other products, Quillivant XR and QuilliChew ER, follow the same standards of efficacy and safety. These medications also make use of Liqui XR technology and come with detailed prescribing information for healthcare professionals, making them reliable choices for ADHD treatment.
Tris Pharma also offers a patient-savings program for its ADHD products. Eligible patients may pay as low as $25 for Tris ADHD treatments, demonstrating the company's commitment to accessible and affordable healthcare.
In conclusion, Tris Pharma presents a multi-product solution for treating ADHD. With various product offerings and a technologically advanced method of medication release, the company demonstrates its dedication to providing efficient and consistent treatment options for patients suffering from ADHD. The company's attention to safety, efficacy, and patient affordability make it a comprehensive resource for healthcare professionals seeking effective ADHD treatment solutions.
